Inhibition of EZH2 activity in the GC-derived DLBCL cells using a small molecule inhibitor was previously shown to reduce global H3K27me3 levels, induce the expression of BLIMP1 (a tumor suppressor) and impair the in vitro growth of lymphoma cells [5]. The gene discussed is PRDM1; the disease is neoplasm.